R
50.49
-0.47 (-0.92%)
| 前收盘价格 | 50.96 |
| 收盘价格 | 51.45 |
| 成交量 | 275,703 |
| 平均成交量 (3个月) | 645,226 |
| 市值 | 916,461,376 |
| 市盈率 (P/E TTM) | 8.16 |
| 预期市盈率 (P/E Forward) | 9.55 |
| 价格/销量 (P/S) | 3.21 |
| 股市价格/股市净资产 (P/B) | 7.65 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业毛利率 | 18.31% |
| 营业利益率 (TTM) | 23.95% |
| 稀释每股收益 (EPS TTM) | 2.09 |
| 季度收入增长率 (YOY) | 80.60% |
| 季度盈利增长率 (YOY) | 1,845.90% |
| 总债务/股东权益 (D/E MRQ) | 544.23% |
| 流动比率 (MRQ) | 2.20 |
| 营业现金流 (OCF TTM) | 35.59 M |
| 杠杆自由现金流 (LFCF TTM) | 3.40 M |
| 资产报酬率 (ROA TTM) | 18.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Rigel Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.1
| 分析师共识 | -1.5 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.13 |
|
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.66% |
| 机构持股比例 | 79.25% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Soleus Capital Management, L.P. | 30 Sep 2025 | 330,010 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 57.00 (HC Wainwright & Co., 12.89%) | 购买 |
| 中 | 42.00 (-16.82%) | |
| 低 | 38.00 (Cantor Fitzgerald, -24.74%) | 保留 |
| 平均值 | 45.67 (-9.55%) | |
| 总计 | 2 购买, 1 保留 | |
| 平均价格@调整类型 | 34.82 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 05 Nov 2025 | 38.00 (-24.74%) | 保留 | 37.85 |
| Jefferies | 05 Nov 2025 | 42.00 (-16.82%) | 购买 | 37.85 |
| HC Wainwright & Co. | 08 Oct 2025 | 57.00 (12.89%) | 购买 | 28.76 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合